These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16046903)

  • 1. Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression?
    Redon J
    Curr Opin Nephrol Hypertens; 2005 Sep; 14(5):448-52. PubMed ID: 16046903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of target organ damage in treated hypertensive patients: different impact of clinic and ambulatory blood pressure control.
    Cuspidi C; Lonati L; Sampieri L; Michev I; Macca G; Rocanova JI; Salerno M; Fusi V; Leonetti G; Zanchetti A
    J Hypertens; 2000 Jun; 18(6):803-9. PubMed ID: 10872567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal protection by antihypertensive drugs: insights from microalbuminuria studies.
    Redon J
    J Hypertens; 1998 Dec; 16(12 Pt 2):2091-100. PubMed ID: 9886902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Masked hypertension and target organ damage in treated hypertensive patients.
    Tomiyama M; Horio T; Yoshii M; Takiuchi S; Kamide K; Nakamura S; Yoshihara F; Nakahama H; Inenaga T; Kawano Y
    Am J Hypertens; 2006 Sep; 19(9):880-6. PubMed ID: 16942927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
    Gerdts E; Papademetriou V; Palmieri V; Boman K; Björnstad H; Wachtell K; Giles TD; Dahlöf B; Devereux RB;
    Am J Cardiol; 2002 Feb; 89(4):399-402. PubMed ID: 11835919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microalbuminuria in primary hypertension: a guide to optimal patient management?
    Viazzi F; Cappadona F; Pontremoli R
    J Nephrol; 2016 Dec; 29(6):747-753. PubMed ID: 27417557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated ambulatory hypertension and changes in target organ damage in treated hypertensive patients.
    Cuspidi C; Meani S; Fusi V; Valerio C; Catini E; Magrini F; Zanchetti A
    J Hum Hypertens; 2005 Jun; 19(6):471-7. PubMed ID: 15744331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural cardiovascular alterations and blood pressure variability in human hypertension.
    Mancia G; Giannattasio C; Turrini D; Grassi G; Omboni S
    J Hypertens Suppl; 1995 Aug; 13(2):S7-14. PubMed ID: 8576791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment.
    Rodilla E; Pascual JM; Costa JA; Martin J; Gonzalez C; Redon J
    J Hypertens; 2013 Aug; 31(8):1683-91. PubMed ID: 23835910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Modern therapy of hypertension].
    Battegay E
    Praxis (Bern 1994); 2003 Dec; 92(50):2153-7. PubMed ID: 14708254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antihypertensive agents on the left ventricle: clinical implications.
    Díez J; González A; López B; Ravassa S; Fortuño MA
    Am J Cardiovasc Drugs; 2001; 1(4):263-79. PubMed ID: 14728026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of metabolic syndrome on hypertension-related target organ damage.
    Mulè G; Nardi E; Cottone S; Cusimano P; Volpe V; Piazza G; Mongiovì R; Mezzatesta G; Andronico G; Cerasola G
    J Intern Med; 2005 Jun; 257(6):503-13. PubMed ID: 15910554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension.
    Pascual JM; Rodilla E; Costa JA; Garcia-Escrich M; Gonzalez C; Redon J
    Hypertension; 2014 Dec; 64(6):1228-34. PubMed ID: 25245391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic importance of baseline and serial changes in microalbuminuria in patients with resistant hypertension.
    Salles GF; Cardoso CR; Fiszman R; Muxfeldt ES
    Atherosclerosis; 2011 May; 216(1):199-204. PubMed ID: 21315356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension.
    Assadi F
    Pediatr Cardiol; 2007; 28(1):27-33. PubMed ID: 17308944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in left ventricular geometry during antihypertensive treatment.
    Salvetti M; Paini A; Bertacchini F; Stassaldi D; Aggiusti C; Agabiti Rosei C; Bassetti D; Agabiti-Rosei E; Muiesan ML
    Pharmacol Res; 2018 Aug; 134():193-199. PubMed ID: 29959031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension and Organ Damage in Women.
    Muiesan ML; Paini A; Aggiusti C; Bertacchini F; Rosei CA; Salvetti M
    High Blood Press Cardiovasc Prev; 2018 Sep; 25(3):245-252. PubMed ID: 29943358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.